Shift in motor-state equilibrium explains gait therapy effects of apomorphine in experimental Parkinsonism

Read full text
Authors: Burçe Kabaoğlu, Elisa L. Garulli, Rafael De Sa, Arend Vogt, Ruben Behrsing, Matej Skrobot, Raik Paulat, Patrick Pollak, Lynn S. Guldin, Moritz Gerster, Wolf-Julian Neumann, Matthias Endres
+2 more Harms Christoph, Nikolaus Wenger
Cited by: 1
References: 55

Abstract

Gait impairments remain a major therapeutic challenge in Parkinson's disease (PD). Apomorphine is gaining renewed clinical attention with the expanding use of pump infusion systems. Yet the specific role of apomorphine on the neural regulation of gait has remained poorly characterized, limiting its targeted use for symptom-specific therapy in PD. Here, we examined the neurobehavioral effects of apomorphine on runway locomotion in the unilateral 6-hydroxydopamine (6-OHDA) rat model. Therapeutic drug doses significantly increased total walking distance, related to reduced akinesia and prolonged gait episodes. Conversely, 3D kinematic analysis revealed reduced limb velocities under medication. At the neural level, therapy doses selectively enhanced cortical high-gamma rhythms without substantially altering beta or low-gamma activity. Instead, beta and low-gamma oscillations were consistently suppressed during motor activity in both medication ON and OFF conditions. Neurobehavioral correlations showed that transitions into gait were facilitated by reductions in beta and low-gamma activity, whereas transitions to akinesia were primarily suppressed when high-gamma activity was elevated. Our findings highlight that cortical oscillations can serve as state specific biomarkers for gait impairments in PD. We further propose that the complex therapy effects of apomorphine are best explained by a shift in motor-state equilibrium that is defined by the transitions of akinesia, stationary movements and gait. Together, these insights establish a mechanistic framework to guide the development of targeted gait therapies in PD. • Apomorphine is a key pharmacological target for gait therapy in PD. • Cortical high-gamma serves as a biomarker for reduced akinesia transitions. • Cortical beta/low-gamma correlates with reduced transitions to gait. • We propose a motor-state equilibrium to explain apomorphine's gait effects. • The concept extends anti- and prokinetic oscillations to multi-state motor regulation.

Fields of Study & Subjects

Neurological disorders and treatments Parkinson's Disease Mechanisms and Treatments Balance Gait and Falls Prevention

Publication details

Journal / source
Experimental Neurology
Publisher
Elsevier BV
Volume
401
Pages
115704–115704
Publication date
27 February 2026
Language
EN